Agenda

 

27-29 October 2025
RAI Congress Center, Amsterdam

 

 

Amsterdam, 27 - 29 October 2025

Schedule

Create your personal agenda –check the favourite icon

Oct 2710:30
Conference pass

Early Access & Patient Advocacy

Clinigen Workshop

Hollistic Approaches to Rare Disease Drug Development: Integrating ESG, Patient Engagement, and Commercial Strategy for Improved EU Access

Session led by: clinigen-group
Oct 2710:30
Conference pass

Working Group 8: Involving Rare Diseases Patients in Clinical Guidelines’ Development

Working Groups
Moderator: Beatriz Carmona-Hidalgo, Postdoctoral Researcher, Junta de Andalucía
Anabel Granja Dominguez, Researcher, Junta de Andalucía
Juan Dario Ortigoza Escobar, Paediatric Neurologist Consultant, Hospital Sant Joan de Déu
Oct 2711:30
Conference pass

Innovation in LMICs: Overcoming Barries to Access and Advancing Global Rare Disease Solutions

Working Groups
Daria Julkowska, Scientific Coordination, European RD Research Alliance, IRDiRC
Debra Bellon, Strategic Engagement Manager, Rare Diseases International
Durhane Wong-Rieger, President, Chief Executive Officer, Canadian Organisation for Rare Disorder & Rare Diseases International
Oct 2714:00
Conference pass

Enabling Digitally-Enhanced Care for Rare Diseases in Europe

Chiesi Workshop

Lysosomal Storage Disorders (LSDs) present significant challenges, including delayed diagnoses, fragmented care pathways, and limited access to specialist care. Digital health technologies offer a transformative opportunity to address unmet needs by enabling earlier intervention, enhancing care coordination, and empowering patients and healthcare providers with innovative tools.

Utilizing interactive tools and featuring multi-stakeholder perspectives from patients to industry and policymakers, this discussion will explore the integration of digital health innovations ranging from AI to telemedicine, digital medical devices, and other connected care technologies into care pathways for rare diseases across Europe

Session led by: chiesi-global-rare-diseases
Enrico Piccinini, Senior Vice President, EU & International, Rare Diseases, Chiesi Group
Maurizio Scarpa, Director, Coordinating Center For Rare Diseases, MetabERN
Pierantonio Russo, FCCP, FAAP, STS, Corporate Chief Medical Officer, EVERSANA
Kim Angel, Executive Director, International MPS Network
Alberta Spreafico, Senior Vice President, Health Innovation, EVERSANA
Oct 2714:00
Conference pass

The Rare Disease Action Plan – Where are we now?

Sanofi Workshop

Rare diseases pose unique challenges to healthcare systems worldwide due to their low prevalence and complex treatment requirements. Traditional financing mechanisms often fail to adequately address the needs of patients with rare diseases, leading to disparities in access to treatment and care. Last June, RDI (Rare Diseases International) launched a campaign for a World Health Assembly (WHA) Resolution on Rare Diseases in 2025. RDI is launching a campaign for a World Health Assembly (WHA) Resolution on Rare Diseases in 2025.

Moderator: Anne-Sophie Chalandon, Head of Global Public Affairs, Rare Diseases and CGT Policies, Sanofi

Create your personal agenda –check the favourite icon

Oct 289:10
Conference pass

Keynote panel: Looking ahead, what does the future hold for Europe’s Life Science Strategy and what does it mean for rare diseases?

Keynotes
Fabienne Bartoli, Inspector General, French National Authority for Health
Christina Kyriakopoulou, Senior Expert - Policy Officer Health Research, European commission
Virginie Bros-Facer, CEO, EURORDIS
Oct 2810:00
Conference pass

Keynote panel: How well has your EUHTA implementation gone?

Keynotes
Niklas Hedberg, Head Of Pharmacy, Tandvards och Lakemedelsformansverket
Anne Willemsen, Co-chair JCA Subgroup, Zorginstituut Nederland
Alexander Natz, Secretary General, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Jonathan Neal, Head of Central, South and Eastern Europe Takeda and EFPIA European Markets Committee, Takeda
Judith Fernandez, Deputy Director - HTA department, Haute Aurotité de santé (HAS)
Oct 2811:30
Conference pass

Working Group 1: How can we manage the tension between immediate access to innovation and affordability?

Working Groups
Bhavesh Patel, Principal, CRA, Charles River Associates
Oct 2811:30
Conference pass

Working Group 2: From Insight to Action: Leveraging Patient Experience Data Across the Rare Disease Lifecycle

Working Groups

Understanding patient experiences, preferences, and behaviours is critical to developing treatments that truly meet patient needs. Yet in rare diseases, capturing and applying these insights remains difficult due to small, diverse populations, delayed diagnoses, a lack of standardized methods, and limited regulatory guidance.

This panel will explore how both qualitative, and semi-quantitative patient data can inform more effective, patient-centred decisions across the product lifecycle in the rare disease space. Experts will address key barriers, such as data integration, resource constraints, and methodological gaps, and share practical strategies and real-world examples to overcome them.

Join the panel and gain a clear view of what meaningful patient experience data look like and how they can drive clinical development strategies, as well as pre-launch and market success

Oct 2811:30
Conference pass

Working Group 3: Shifting Strands: Operational Challenges and Ethical Dilemmas of Genetic Testing

Working Groups
Drew Matheson, Executive Director. Franchise Area Lead Respiratory Medicine and Infectious Disease, Worldwide Clinical Trials
Oct 2811:30
Conference pass

Working Group 5: Changes in orphan drug legislation and patient access

Working Groups

Reserved for Clinigen

Oct 2811:30
Conference pass

Working Group 6: Challenge of Demonstrating Clinical Meaningfulness in the Context of Rare Disease

Working Groups

Reserved for Decisive Consulting

Oct 2814:10
Conference pass

Horizon scanning towards better payer decision making

Access & Pricing
Moderator: Marcus Guardian, CEO, International Horizon Scanning Initative
Oct 2814:10
Conference pass

Landscape Analysis from the Bottom Up: Letting the Patients Tell You Which Sites to Use in Your Rare Disease Trial

Clinical Development
Juliet Moritz, Senior VP Strategic Solutions and Patient Centricity, Ergomed
Oct 2814:10
Conference pass

Panel: Platform approach to GLP – moving away from product authorization

Cell & Gene Therapy

To invite:

Constanz Blume, Global Regulatory Affairs, BionTech

Kent Rogers, CEO, Everyone Medicines

Senior EMA Representative

Moderator: Alexander Natz, Secretary General, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Oct 2814:10
Conference pass

Regulatory Convergence – innovative approaches for clinical research showcasing ERDERA-INVENTS results

Science & Strategy

Senior Representative, ERDERA

Oct 2814:10
Conference pass

Strategies for securing early stage funding and maximising fundraising opportunities

Investment & Funding
Thom Frielink, Associate, Curie Capital BV
Oct 2814:10
Conference pass

The growing influence of patient voices in Rare

Patient Centricity

Senior Representative, UCB

Oct 2814:10
Conference pass

The need for better diagnosis in rare primary immunodeficiencies

Precision Medicine

Senior Representative, EUCOPE

Oct 2814:10
Conference pass

The utilisation of healthcare resource and economic burden on patients living with rare diseases – Title TBC

Real World Evidence

Reserved for EVERSANA

Session led by: eversana
Oct 2814:15
Conference pass

Uncovering genetically defined patients for improved diagnosis, drug development and commercial strategy

BioPharma Showcases
Karen Malone, CEO, GeneScape
Oct 2814:25
Conference pass

Natural history studies of how to understand a rare disease

Clinical Development
Christopher Rudolf, Founder and Chief Executive Officer, Volv Global
Leon van Wouwe, Clinical Innovation Director, Volv Global
Oct 2814:30
Conference pass

How to scale individualized therapies – perspectives from the front lines

BioPharma Showcases
Oct 2814:40
Conference pass

AI & the use of DHT Technologies

Precision Medicine
Violeta Stoyanova-Beninska, Senior Scientific Specialist at Human Division EMA, Chair of Regulatory Science Committee, IRDiRC, EMA
Oct 2814:40
Conference pass

Challenges of Late onset Rare diseases – recommendations from the COLLABORATE Consensus Paper From Complexity to Clarity: Overcoming Reimbursement Challenges for Orphan Drugs

Access & Pricing
Elise Evers, Senior Consultant, Initiate
Georgia Roberts, Senior Consultant HTA, Initiate
Oct 2814:40
Conference pass

CollaboRARE: How to collect patient experience data for regulatory use – Title TBC

Patient Centricity
Moderator: Maria Cavaller Bellaubi, Patient Engagement and Therapeutic Development Director, EURORDIS
Julian Isla, Director, Foundation 29
Oct 2814:40
Conference pass

Optimizing Clinical Trial Design for Orphan Drugs: Addressing Recruitment, Efficacy, and Safety in Rare Diseases

Clinical Development
Carlos Pinoargote, Chief Operating Officer, BRCR Global
Session led by: brcr-global
Oct 2814:40
Conference pass

The use of Delphi Panels in RWE

Real World Evidence

Senior Representative, Costello

Session led by: costello-medical-consulting-ltd
Oct 2814:40
Conference pass

What funding opportunities can patient groups maximise to advocate for new treatments?

Investment & Funding
Stefano Benvenuti, Head of Public Affairs and Market Access, Fondazione Telethon
Federica Miotto, head of medical affairs, Fondazione Telethon
Oct 2814:45
Conference pass

ALEETO™️, protein complex derived from stimulated stem cells, a novel neural repair reagent from bench to clinic

BioPharma Showcases
Oct 2814:50
Conference pass

IRDiRC Taskforce on prevention: Opportunities and Challenges in the shift from treatment to prevention

Science & Strategy

More speakers to be confirmed..

Moderator: Daniel O'Connor, Director, Regulatory Policy & Early Access, ABPI
Oct 2814:55
Conference pass

Panel: How will be the JCA for ATMPs? Questions and answers from the ATMP ecosystem

Cell & Gene Therapy

More speakers to be confirmed..

Moderator: Mark Battaglini, Chief Strategy Officer, Alliance for Regenerative Medicine
Paolo Morgese, Vice President, Public Affairs, Europe, Alliance for Regenerative Medicine
Oct 2815:00
Conference pass

Rare disease registries - Title TBC

BioPharma Showcases
Oct 2815:10
Conference pass

Aspire4Rare: Acting Now for People Living with Rare Diseases

Access & Pricing

Senior Representative, UCB

Oct 2815:10
Conference pass

Beyond Recruitment: The Value of Patient and Care Network Education in Rare Disease Clinical Research

Patient Centricity
Paula Orandash, Director, Patient Engagement, Ergomed
Oct 2815:10
Conference pass

Bridging the Gap: Clinical Trials as a Standard of Care in Rare Diseases

Clinical Development
Derek Ansel, Vice President, Therapeutic Strategy Lead, Rare Disease, Worldwide Clinical Trials
Oct 2815:10
Conference pass

Leveraging Compassionate Use Programs to Accelerate Investigational Drug Development in the United States

Real World Evidence
Ana Tediosi, Head of Expanded Access Program Strategy, WEP Clinical
Session led by: worldwide-clinical-trials
Oct 2815:10
Conference pass

The Role of Foundations in Advancing Rare Disease Research: Funding Models and Success Stories

Investment & Funding
Sebastian Honoré, Cure Lowe Foundation
Oct 2815:10
Conference pass

The role of patient advocacy in access to whole genome sequencing for cancer of unknown primary

Precision Medicine
Oct 2815:30
Conference pass

Clinical stage program on rare genetic disease Hypophosphatasia

BioPharma Showcases
Juliane Bernholz, Chief Operating Officer, A.M. Pharma
Oct 2815:45
Conference pass

What kind of data/assets can patient groups bring into pre-clinical or clinical development?

BioPharma Showcases
Ron Jortner, Founder & CEO, Aspire Biosciences
Oct 2816:00
Conference pass

Metabolic plasmalogen replacement therapy for a rare peroxisomal disorder – Title tbc

BioPharma Showcases
Oct 2816:10
Conference pass

AI and it’s use in access and pricing

Access & Pricing
Sven Tops, Chief Market Access Officer, Kintiga
Oct 2816:10
Conference pass

An integrated approach to gathering the voice of the patient in an ultra-rare pediatric disease

Patient Centricity
Oct 2816:10
Conference pass

Panel: Innovative funding mechanisms and business models to de-risk Orphan Drug investment

Investment & Funding

Invited:

Francis Pang, SVP, Global Market Access & International Geographic Expansion, Orchard Therapeutics

Liz Fowler, Former Director, CMS Innovation Center; Former VP, Global Health Policy, J&J

Rosana Sovani, Partner, Head of Legal Public Affairs, LS CUBE Studio Legale

Moderator: Victor Maertens, Government Affairs Director, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
Oct 2816:10
Conference pass

Panel: Issues on how to characterise rare diseases

Science & Strategy

Invited:

Senior HTA Representative

Senior Clinician

Senior Geneticist

Moderator: Sheela Upadhyaya, Life Science Advisor in Rare Diseases & Special Advisor, Openflex Ltd
Oct 2816:10
Conference pass

Panel: The use of rare disease registries – bridging the gap between regulatory and patients

Real World Evidence

Invited speakers:

Prof. Peter Mol, Professor, Drug Regulatory Science, University Medical Center Groningen, CHMP Member, CBG-MEB

Senior ERN Representative

Senior Patient Representative

Moderator: Karen Facey, Senior Research Fellow, University of Edinburgh
Oct 2816:10
Conference pass

Reimbursement timelines and key access challenges for Cell & Gene therapies in the Netherlands vs other EU countries

Cell & Gene Therapy
Angela Borghouts - de Ruijter, Associate Director Market Access, Gilead Sciences
Oct 2816:10
Conference pass

Sustainability of lifetime dosing for antisense oligonucleotides in rare diseases: The need for scalable national models

Clinical Development
Rachel Smith, Executive Director, Global Head of Rare Disease, CoE, Parexel
Oct 2816:10
Conference pass

The First Closed-Loop Breathing Pacemaker: Toward an Artificial Pancreas Respiratory Drive

Precision Medicine
James Oakley, CEO, Keep Me Breathing
Oct 2816:25
Conference pass

Integrating market access into regulatory strategies

Access & Pricing
Oct 2816:30
Conference pass

A new definition of Unmet Medical Need in EU pharma legislation; impact on innovation and access for patients

Cell & Gene Therapy
Thomas Bols, Head of Government Affairs and Patient Advocacy, EMEA & APAC, PTC Therapeutics
Oct 2816:40
Conference pass

Panel: EU’s Rare Opportunity: Navigating the new Joint Clinical Assessment route in Europe

Access & Pricing

Senior Representative, EVIDERA

more speakers to be confirmed

Julien Delaye, Patient Engagement Manager – HTA, EURORDIS, EURORDIS
Oct 2816:40
Conference pass

Patient centricity – from ambition to implementation

Patient Centricity
Dieter Schultewolter, Head of Global Medical Affairs Neuroscience, Teva Pharmaceuticals
Andy Barrick, CEO, Multiple System Atrophy Trust UK
Oct 2816:40
Conference pass

Rare Kidney conditions HE Report

Clinical Development
Aisling McMahon, Kidney Research UK
Oct 2816:50
Conference pass

A gene therapy approach for ARSACS: insights from preclinical models

Cell & Gene Therapy
Daniele De Ritis, Researcher, San Raffaele Scientific Institute
Francesca Maltecca, Group Leader, San Raffaele Scientific Institute
Oct 2816:55
Conference pass

Considerations when conducting your rare pediatric programmes

Clinical Development
Jonathan Kornstein, VP, Rare Disease & Pediatrics Clinical Development, Caidya
Oct 2817:10
Conference pass

Diversity and Equity in Clinical Studies: Impact on Rare Disease Studies

Clinical Development
Corinne Blanchet, Executive Director, Program Delivery, Premier Research
Session led by: premier-research

Create your personal agenda –check the favourite icon

Oct 299:00
Conference pass

Keynote Panel: Leveraging new technology for smarter decision-making in Rare Disease drug development and access

Keynotes
Moderator: Claire Skentelbery, Director General, EuropaBio
Christopher Rudolf, Founder and Chief Executive Officer, Volv Global
Julian Isla, Director, Foundation 29
Stelios Kympouropoulos, MEP, European Parliament
Mohit Jain, Vice President, Market Access, International Operations, IntraBio
Wim Goettsch, Special Advisor HTA & Professor for HTA of Pharmaceuticals, Zorginstituut
Michael Merchant, National Institute for Health and Care Excellence
Oct 299:45
Conference pass

Keynote panel: New treatments on the block – 2025’s rare disease pipeline

Keynotes
Moderator: Paolo Morgese, Vice President, Public Affairs, Europe, Alliance for Regenerative Medicine
P.J. Brooks, Deputy Director, Division of Rare Diseases Research Innovation, NIH/NCATS
Violeta Stoyanova-Beninska, Senior Scientific Specialist at Human Division EMA, Chair of Regulatory Science Committee, IRDiRC, EMA
Gabriella Almberg, Head of Health System Policy & Public Affairs, UCB
Oct 2911:15
Conference pass

Accelerating rare disease diagnosis beyond birth

Precision Medicine
Stefano Portolano, CEO, Azafaros
Oct 2911:15
Conference pass

Access and HTA pathways for OMPs – do they improve access and drive incentive for innovation?

Access & Pricing

Senior Representative, Ipsen

Session led by: ipsen
Oct 2911:15
Conference pass

Advancement of analytical tools for testing and characterization of AAV gene therapy products

Manufacturing
Bart van Montfort, Scientific Director Biologics & Scientific Leader Gene Therapy, Johnson and Johnson
Oct 2911:15
Conference pass

Diversifying Rare Disease Research: Strategies for Expanding Participation

Clinical Development

Senior Representative, Allucent

Session led by: allucent
Oct 2911:15
Conference pass

DMAb Technology: The Transformational Potential of Next Gen DNA Medicine in Rare Disease

Cell & Gene Therapy
Trevor Smith, VP Preclinical R&D, Inovio Pharmaceuticals
Oct 2911:15
Conference pass

Panel: Defining the building blocks to enhance the research and therapeutic development pathway to be more psychologically informed

Patient Centricity
Matt Bolz-Johnson, Mental Health Lead & Healthcare Advisor, EURORDIS
Oct 2911:15
Conference pass

Panel: Launch to Global – Best practices to successfully launch Orphan Drugs in Europe

Science & Strategy

Senior Representative, Mereo Pharma

Oct 2911:15
Conference pass

Strategic use of RWD for the use towards HTA submissions

Real World Evidence

Invited:

Frauke Naumann-Winter, Committee for Orphan Medicinal Products, Institute for Drugs and Medical Devices – TBC

Oct 2911:45
Conference pass

Maximizing Value & Positioning in the Emerging Competitive Rare Disease Arena

Access & Pricing
Bhavesh Patel, Principal, CRA, Charles River Associates
Oct 2911:45
Conference pass

Navigating the Uncharted: Patient Experience Mapping in Rare Disease

Real World Evidence

Senior Representative, Ipsen

Session led by: ipsen
Oct 2911:45
Conference pass

Panel: Competition of regulatory ecosystems in approving medicines: policy implications in the case of Europe

Science & Strategy
Moderator: Pedro Franco, Head of Europe Global Regulatory and Scientific Policy, Merck
Oct 2911:45
Conference pass

Panel: Ensuring ATMP Manufacturing Excellence in EU – the need for a policy framework and opportunities in the Biotech Act

Manufacturing

Invited speakers:

Senior Representative, Miltenyi Biotech

Senior Representative, European Commission

More to be confirmed..

Moderator: Victor Maertens, Government Affairs Director, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
Oct 2911:45
Conference pass

Panel: The Impact of Biotechnology: Evolution and Revolution in Rare Diseases

Cell & Gene Therapy

Senior Representative, HollandBio

Moderator: Claire Skentelbery, Director General, EuropaBio
Adrien Samson, Healthcare policy senior manager, EuropaBio
Oct 2911:45
Conference pass

Personalised medicine dilemma – how do we generate data?

Precision Medicine

Senior ERN Representative

Oct 2911:45
Conference pass

Rare Kidney conditions HE Report

Clinical Development
Aisling McMahon, Kidney Research UK
Oct 2912:00
Conference pass

Panel: Implications of EU HTA Joint Clinical Assessments to Patient Engagement Practices in Rare Diseases

Patient Centricity

This panel will explore thepractical implications that industry and patient organizations need to consider when engaging given the evolving landscape of HTA in Europe

Moderator: Veronica Lopez Gousset, Independent Consultant, VLG Consulting
Alexander Natz, Secretary General, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Sheela Upadhyaya, Life Science Advisor in Rare Diseases & Special Advisor, Openflex Ltd
Oct 2912:15
Conference pass

Convergence on rare disease and precision medicine – a real drive on drug development and patient advocacy

Precision Medicine
Durhane Wong-Rieger, President, Chief Executive Officer, Canadian Organisation for Rare Disorder & Rare Diseases International
Oct 2912:15
Conference pass

How do you assess evidence in Rare? The work of HTAi RDIG

Access & Pricing
Alicia Granados, Head, Global Rare Diseases Medical Scientific Advocacy, Sanofi
Oct 2912:15
Conference pass

Unique Challenges in Recruiting Patients for Rare Indication Paediatric Studies: Overcoming Difficulties through a Site and CRO Perspective

Clinical Development
Rachel Paiva Petean Abu Taleb, Medical Monitor, Veristat
Oct 2912:15
Conference pass

Volume and willingness to pay – strengthening access to medicines for rare diseases to sustainable costs

Real World Evidence

Invited:

Sofie Alverlind,Coordinator and Project Leader,TLV

Oct 2913:45
Conference pass

MoCA and JSC in practice - a multistakeholder perspective

Access & Pricing
Sarka Kubinova, Medical evaluator, MoCA coordinator, Czech Republic State Institute for Drug Control
Oct 2913:45
Conference pass

Navigating FDA Processes, including overcoming a partial clinical hold

Clinical Development

Senior Representative, Rezolute Bio

Oct 2913:45
Conference pass

New platforms for RNA therapy development and regulatory considerations – ERDERA

Cell & Gene Therapy
Daria Julkowska, Scientific Coordination, European RD Research Alliance, IRDiRC
Oct 2913:45
Conference pass

Panel: Drug Repositioning – How to get shelved assets that have value for the Orphan drug value chain

Science & Strategy
Moderator: Annette Bakker, CEO, Childrens Tumor Foundation
Oct 2913:45
Conference pass

Panel: Exceptional Use of an Orphan Drug for an Ultra Rare Disease

Real World Evidence
Denis Broun, Director Givopax, Former Executive Director of UNTAID, World Health Organization, & Medical Director, Menkes International Association
Elena Godoy, Attending Pediatrician, Department of Pediatrics, Málaga Regional University Hospital
Oct 2913:45
Conference pass

The EU Biotechnology and Biomanufacturing Initiative Opportunities for Investment into Rare Disease Innovation and delivery

Manufacturing
Adrien Samson, Healthcare policy senior manager, EuropaBio
Claire Skentelbery, Director General, EuropaBio
Oct 2913:45
Conference pass

The story of Marco: Ultra rare case study towards the treatment of Menkes Disease

Patient Centricity
Oct 2914:00
Conference pass

ARSACS (Ataxia Charlevoix-Saguenay): Finding Solutions for Rare Disease Patients – title TBC

Patient Centricity

Invited speaker:

Dr. Bart Van de Warrenburg, Professor of Neurology & Medical Lead, Center for Rare and Genetic movement disorders, Radboudumc

Sonia Gobeil, Cofounder, Ataxia of Charlevoix-Saguenay Foundation
Oct 2914:05
Conference pass

Transitioning from US coordinated clinical trials to commercialization in Europe

Clinical Development
Tom Pulles, MD, VP, Head of Medical Affairs & Patient Advocacy, Europe, Acadia Pharmaceuticals Inc.
Oct 2914:05
Conference pass

Will the bubble burst on rare disease and orphan drugs? Paying for innovation and access.

Access & Pricing
Oct 2914:10
Conference pass

Strategies for securing early stage funding and maximising fundraising opportunities

Investment & Funding
Thom Frielink, Associate, Curie Capital BV
Oct 2914:25
Conference pass

Strategic Evidence Generation – Exploring Multiple Stakeholder Needs

Access & Pricing
Josie Godfrey, Director, JG Zebra Consulting
Oct 2914:25
Conference pass

The Role of Basket & Umbrella Clinical Trials in Tackling Rare Diseases

Clinical Development

Senior Representative, C-Path

Oct 2914:30
Conference pass

ATMPs: Essential Tools or Essential Medicines?

Cell & Gene Therapy

Senior Representative, Miltenyi Biotec

Oct 2914:30
Conference pass

Orphan Drug Access Protocols

Real World Evidence
Oct 2914:30
Conference pass

Pharmacometrics and manufacturing for exceptional use of an orphan drug

Manufacturing
Denis Broun, Director Givopax, Former Executive Director of UNTAID, World Health Organization, & Medical Director, Menkes International Association
Oct 2914:30
Conference pass

Unmet Medical Need in Haemophilia

Patient Centricity

Invited:

Senior Representative, Novo Nordisk

European Hemophilia Consortium

ERN Blood

Oct 2914:45
Conference pass

Patients voice in clinical trials design and outcomes

Clinical Development

Senior Representative, FH Europe

Oct 2915:40
Conference pass

Panel: Driving Patient-Centric Innovation: Pharma’s Involvement and Stakeholder Collaboration

Patient Centricity

More speakers to be confirmed..

Oct 2916:30
Conference pass

Keynote Panel: In what way can we mobilise, enable and leverage international policies around the world for PLWRDs?

Keynotes

Invited: Dr Mohamed Hassany, Assistant Minister for Public Health Initiative, Ministry of Health Egypt

Moderator: Yann Le Cam, Founder & Past-CEO of EURORDIS-Rare Disease Europe, EURORDIS-Rare Diseases Europe
Anne-Sophie Chalandon, Head of Global Public Affairs, Rare Diseases and CGT Policies, Sanofi
Alexandra Heumber Perry, Chief Executive Officer, Rare Diseases International
Nadiah Hanim Abdul Latif, President, Malaysian Rare Disorders Society
last published: 19/Jun/25 12:15 GMT

Get involved at World Orphan Drug Congress Europe 2025

 

 

TO SPONSOR


Steph Scanlon

Steph.Scanlon@terrapinn.com

 

TO SPEAK


Abdu Kauroo
Abdu.Kauroo@terrapinn.com

 

MARKETING & PRESS


Jasper Cameron

Jasper.Cameron@terrapinn.com

 

Stay Up-to-Date

Join our mailing list to receive exclusive content and offers.

By submitting, you agree to receive email communications from Terrapinn, including upcoming promotions and discounted tickets and news.